Raising the Bar in Pediatric Survivorship Care and Research

We invite you to join us live, in-person at Rockefeller Research Laboratories for this one-day complimentary symposium honoring Charles A. Sklar, MD, which will provide a comprehensive overview of the history of and current standards of pediatric survivorship care and research. Themes will include a history of survivorship research, endocrine late effects of childhood cancer therapy, and MSK's survivorship program and progress. There will also be opportunities for discussion and collaboration for the future directions of survivorship research. A virtual option is available if you are unable to join us in person.

Rockefeller Research Laboratories
430 East 67th Street
New York, NY 10065
Parking | Get Directions

Who Should Attend

This symposium is intended for physicians and healthcare professionals interested in pediatric oncology survivorship, co-morbidities, and long-term care. Registration for this symposium is complimentary for all attendees.

1. Review and discuss novel and/or latest research in pediatric oncology survivorship and long term effects
2. Address issues concerning the pediatric oncology survivor patient population

Registration for this symposium is complimentary for all to attend. Please select the 'Register' tab above to complete registration for this symposium. Instructions on claiming CME credit will be emailed to following the end of the course. 

Virtual Registrants: Access details, including a link to Zoom and faculty disclosures are included in the confirmation email you will receive after your registration is complete. 

Cancellation Policy

MSK CME reserves the right to cancel or postpone any course due to unforeseen circumstances. In the unlikely event we must cancel or postpone this course, you will be notified via email from MSK CME ([email protected]). A full refund will be issued for your registration. MSK CME is not responsible for any related costs, charges, or expenses to participants, including fees incurred by airline/travel/lodging agencies.

If you register for this program and no longer able to attend, please email [email protected].

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

MSK designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

MSK Course Director 

Danielle Novetsky Friedman, MD
Assistant Attending
Department of Pediatrics 

Faculty

David Abramson, MD 
Chief, Ophthalmic Oncology Service, Department of Surgery
Memorial Sloan Kettering Cancer Center

Zoltan Antal, MD 
Associate Professor and Chief of Pediatric Endocrinology at Weill Cornell
Weill Cornell Medicine and MSK Kids 

Smita Bhatia, MD  
Director of the Institute for Cancer Outcomes and Survivorship, UAB School of Medicine 
Vice Chair for Outcomes, Department of Pediatrics
University of Alabama at Birmingham 

Farid Boulad, MD 
Vice Chair, Clinical Operations
Medical Director, Pediatric Ambulatory Care
MSK Kids, Memorial Sloan Kettering Cancer Center

Wassim Chemaitilly, MD 
Clinical Director, Division of Pediatric Endocrinology, Diabetes and Metabolism 
UPMC Children’s Hospital of Pittsburgh 

Lisa DeAngelis, MD 
Physician-In-Chief
Memorial Sloan Kettering Cancer Center 

Deborah Diotallevi, PNP
Pediatric Long-Term Follow-Up 
MSK Kids, Memorial Sloan Kettering Cancer Center

Ira Dunkel, MD  
Member, Neuro-Oncology Service 
MSK Kids, Memorial Sloan Kettering Cancer Center 

Danielle Friedman, MD, MS 
Director, Pediatric Long-Term Follow-Up Program
MSK Kids, Memorial Sloan Kettering Cancer Center

Tara Henderson, MD 
Chief, Section of Pediatric Hematology, Oncology and Stem Cell Transplantation
University of Chicago 

Melissa Hudson, MD 
Director, Cancer Survivorship Division
Co-Leader, Cancer Control and Survivorship Program
St. Jude Children’s Research Hospital

Yasmin Khakoo, MD
Member and Director, Child Neurology Program
MSK Kids, Memorial Sloan Kettering Cancer Center

Andrew Kung, MD, PhD
Chair, Department of Pediatrics
MSK KIDS, Memorial Sloan Kettering Cancer Center

Brian Kushner, MD 
Member, Neuroblastoma Service 
MSK Kids, Memorial Sloan Kettering Cancer Center 

Michael LaQuaglia, MD 
Joseph H. Burchenal Chair in Pediatrics, Departments of Surgery and Pediatrics 
Memorial Sloan Kettering Cancer Center

Paul Meyers, MD
Vice Chair, Department of Pediatrics 
Chief, Sarcoma Service
MSK Kids, Memorial Sloan Kettering Cancer Center 

Chaya Moskowitz, PhD 
Member, Department of Epidemiology and Biostatistics
Memorial Sloan Kettering Cancer Center 

Sogol Mostoufi-Moab, MD, MSCE 
Associate Professor, Perelman School of Medicine at the University of Pennsylvania 
Children’s Hospital of Philadelphia 

Kevin Oeffinger, MD 
Director, Duke Cancer Institute (DCI) Center for Onco-Primary Care, and Director of the DCI 
Supportive Care and Survivorship Center 
Duke University 

Richard O’Reilly, MD  
Claire L. Tow Chair in Pediatric Oncology Research 
MSK Kids, Memorial Sloan Kettering Cancer Center 

Elaine Pottenger, PNP
Pediatric Long-Term Follow-Up 
MSK Kids, Memorial Sloan Kettering Cancer Center

Leslie Robison, PhD 
Chair, Department of Epidemiology and Cancer Control
St. Jude Children’s Research Hospital

Stephen Sands, PsyD
Member, Neuropsychology Service
Memorial Sloan Kettering Cancer Center 

Charles Sklar, MD 
Professor Emeritus and Founding Director, Pediatric Long-Term Follow-Up 
MSK Kids, Memorial Sloan Kettering Cancer Center
 
Emily Tonorezos, MD MPH
Director, Office of Cancer Survivorship 
National Cancer Institute

Suzanne Wolden, MD  
Member, Department of Radiation Oncology 
Memorial Sloan Kettering Cancer Center

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

Friday, April 1, 2022